Canaccord analyst Edward Nash raised the firm’s price target on Madrigal Pharmaceuticals to $338 from $336 and keeps a Buy rating on the shares. The firm said they are confident in the potential approval of resmetirom next week and so are increasing their12-month target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MDGL:
- Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Madrigal Pharmaceuticals initiated with a Buy at Citi
- Madrigal Pharmaceuticals announces EMA validation of its MAA for resmetirom
- Madrigal Pharmaceuticals price target raised to $320 from $300 at Oppenheimer
- Madrigal Pharmaceuticals appoints Mardi Dier as CFO